Inflexal V
Sponsors
Crucell Holland BV
Conditions
Influenza
Phase 3
Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V
CompletedNCT01229397
Start: 2010-10-31End: 2010-11-30Updated: 2014-02-06
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
CompletedNCT01310400
Start: 2009-10-31End: 2010-01-31Updated: 2014-02-06
Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains
CompletedNCT01631110
Start: 2012-07-31End: 2012-08-31Updated: 2013-12-20
Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)
CompletedNCT01893177
Start: 2013-07-31End: 2013-08-31Updated: 2013-08-30
Phase 4
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere
CompletedNCT01303510
Start: 2008-07-31End: 2008-07-31Updated: 2013-09-09
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere
CompletedNCT01306305
Start: 2010-06-30End: 2010-07-31Updated: 2013-09-09
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere
CompletedNCT01306253
Start: 2009-06-30End: 2009-06-30Updated: 2013-09-09
A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season
CompletedNCT01457027
Start: 2011-10-31End: 2012-08-31Updated: 2013-02-20